Bromopride

Bromopride is a selective, irreversible, competitive, and orally effective dopamine D2 receptor antagonist. Bromopride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting)^[1][2]. In Vitro:Axon regeneration assay: Bromopride (100 μM; 5 d) significantly promotes axon regeneration in a rat cortical neuron scratch injury model and reversed the inhibitory effect of chondroitin sulfate proteoglycan (CSPG) on axon growth^[1].
Metabolite analysis assay: Bromopride (10 μM; 4 h) can be metabolized into 20 metabolites in mouse, rat, rabbit, dog, monkey and human hepatocytes^[2]. In Vivo:Rat sexual behavior model: Bromopride (20-60 mg; intravenous injection; single dose) dose-dependently inhibited male rat mating behavior (such as prolonged post-ejaculation latency) and increased serum prolactin levels^[2].
Rat peritonitis model: Bromopride (1 mg/kg; subcutaneous injection; every 12 hours; 3/7 days) significantly reduced abdominal wall wound edema and fibrin deposition in Wistar rats with induced peritonitis 7 days after surgery, without affecting wound breaking strength^[3].